This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).
Documented informed consent of the participant and/or legally authorized representative
Women with documented metastatic HER2 positive breast cancer (American Society of Clinical Oncology [ASCO] College of American Pathologist [CAP] guidelines) who have brain metastases
Age > 18 years
Eastern Cooperative Oncology Group (ECOG) 0-2
Need for immediate local intervention for brain metastases
Noninfectious interstitial lung disease or pneumonitis requiring glucocorticoids
Clinically significant corneal disease
Myocardial infarction < 6 months before, congestive heart failure (CHF), unstable angina, or serious cardiac arrhythmia
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator